Adalimumab Pen 40 mg/0.8 mL, 40 mg/0.4 mL Suppliers & Bulk Manufacturers
Available Forms: Pre-filled Syringe or Pen
Available Strengths: 40 mg/0.8 mL, 40 mg/0.4 mL
Reference Brands: Humira (US & EU), Exemptia (India)
Category: Arthritis
Adalimumab is a monoclonal antibody that binds to TNF-alpha, a cytokine involved in inflammation and immune response. It reduces inflammation, tissue damage, and symptoms in rheumatoid arthritis. Benefits include rapid symptom relief, improved joint function, reduced disease progression, and convenient subcutaneous administration, enhancing patient adherence and quality of life.
Product Description:
Adalimumab pen is approved in the EU and US for rheumatoid arthritis and other autoimmune diseases. In the EU, brands like Humira are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and quality. In the US, FDA approval is based on extensive clinical data, biosimilarity assessments, and pharmacovigilance. Both regions require detailed dossiers for approval and continued safety monitoring. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We support efficient market access for adalimumab pens, ensuring adherence to European and American standards for safe, effective biologic therapy, and helping you navigate complex regulatory processes seamlessly.
Adalimumab Pen — third party manufacturing & bulk supply
Adalimumab Pen 40 mg/0.8 mL, 40 mg/0.4 mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Manufacturers of Adalimumab Pen listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Adalimumab Pen →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Adalimumab Pen is used to treat several autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and certain inflammatory conditions.
Adalimumab is a recombinant human monoclonal antibody that targets and blocks tumor necrosis factor-alpha (TNF-α), a substance in the body that causes inflammation in autoimmune diseases.
Common trade names include Humira, Amgevita, Hyrimoz, Idacio, Hadlima, Yuflyma, and Exemptia.
The original brand Humira was developed and marketed by the pharmaceutical company AbbVie, while several pharmaceutical companies produce biosimilar adalimumab products worldwide.
The generic name is Adalimumab.
Common brand names include Humira, Amgevita, Hyrimoz, Idacio, Hadlima, Yuflyma, and Exemptia.
Adalimumab Pen is manufactured in several countries including the United States, Germany, India, and other regions by different pharmaceutical manufacturers.
Related Products
Pegloticase Injecatble
Strength:
8 mg/1.2 mL vial
Form: Injectable (IV solution)
Reference Brands: Krystexxa (US)
View Details
Febuxostat Tablets
Strength:
40 mg, 80 mg
Form: Oral Tablets
Reference Brands: Uloric(EU & US)
View Details
Allopurinol Tablets
Strength:
100 mg, 300 mg
Form: Oral Tablets
Reference Brands: Aloprim(US & EU)
View DetailsQuick Response Guaranteed | Verified Suppliers
